First Choice Healthcare Solutions (FCHS) 10-Q 14 Aug 24 2024 Q2 Quarterly report Financial data

Cover

Cover - $ / shares	6 Months Ended
	Jun. 30, 2024	Aug. 01, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	000-53012
Entity Registrant Name	FIRST CHOICE HEALTHCARE SOLUTIONS, INC.
Entity Central Index Key	0001416876
Entity Tax Identification Number	90-0687379
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	95 Bulldog Blvd
Entity Address, Address Line Two	Suite 202
Entity Address, City or Town	Melbourne
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32901
City Area Code	(321)
Local Phone Number	725-0090
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		32,958,288
Entity Listing, Par Value Per Share	$ 0.001

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,516	$ 12,607
Accounts receivable, net	81,974	92,444
Deposits	466,552
Other Current Assets	2,385	206,631
Total current assets	552,427	311,682
Property, plant and equipment, net	244,879	262,243
Operating lease right-of-use assets	2,279,245	2,437,358
Deferred tax asset	111,949	111,949
Total assets	3,188,500	3,123,232
Current liabilities:
Accounts payable and accrued expenses	9,132,809	8,410,879
Operating lease liabilities, current portion	297,501	299,244
Notes payable, current portion	21,821,446	19,217,018
Total current liabilities	31,251,756	27,927,141
Long term liabilities:
PPP loan payable	1,283,624	1,283,624
Operating lease liabilities, non-current portion	2,297,291	2,442,519
Convertible notes
Total liabilities	34,832,671	31,653,284
Stockholders’ equity (deficit):
Series A Convertible Preferred stock; $0.01 par value, 40,000 shares authorized, 147 and 147 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	1	1
Common stock, $0.001 par value, 100,000,000 shares authorized 32,958,288 and 32,958,288 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively	32,958	32,958
Additional paid-in capital	35,323,578	35,369,995
Treasury stock, 74,453 common shares, at cost
Accumulated deficit	(67,000,708)	(63,933,006)
Total stockholders’ equity (deficit)	(31,644,171)	(28,530,052)
Total liabilities and stockholders’ equity (deficit)	$ 3,188,500	$ 3,123,232

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	40,000	40,000
Preferred stock, shares issued	147	147
Preferred stock, shares outstanding	147	147
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	32,958,288	32,958,288
Common stock, shares outstanding	32,958,288	32,958,288
Treasury stock, shares	74,453	74,453

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue
Revenue, net of discounts	$ 3,303	$ 58,832	$ 10,154	$ (26,006)
Cost of sales
Gross (deficit) profit	3,303	58,832	10,154	(26,006)
Operating expenses
Compensation expense	111,661	171,213	219,155	357,269
Selling, general and administrative expenses	370,637	695,482	766,820	1,501,514
Total operating expenses	482,298	866,695	985,975	1,858,783
Operating loss	(478,995)	(807,863)	(975,821)	(1,884,789)
Other income (expenses)
Gain (loss) on sale of equipment	1,550	24,816	4,150	18,691
Miscellaneous income (expense)
Interest expense, net	(1,384,916)	(1,871,910)	(2,096,033)	(2,809,910)
Total other income (expenses), net	(1,383,366)	(1,847,094)	(2,091,883)	(2,791,219)
Net Loss before income taxes	(1,862,361)	(2,654,958)	(3,067,704)	(4,676,009)
Income taxes expense (benefit)
Net loss	(1,862,361)	(2,654,958)	(3,067,704)	(4,676,009)
Preferred stock dividends	(23,206)	(22,721)	(46,415)	(44,315)
Net loss attributable to common shareholders	$ (1,885,567)	$ (2,677,679)	$ (3,114,119)	$ (4,720,324)
Basic and diluted income (loss) per common share
Basic net loss per common share	$ (0.06)	$ (0.08)	$ (0.09)	$ (0.14)
Diluted net loss per common share	$ (0.06)	$ (0.08)	$ (0.09)	$ (0.14)
Basic weighted average common shares outstanding	32,958,288	32,958,288	32,958,288	32,958,288
Diluted weighted average common shares outstanding	32,958,288	32,958,288	32,958,288	32,958,288

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2023	$ 32,958	$ 1	$ 35,369,995	$ (63,933,006)	$ (28,530,052)
Balance, shares at Dec. 31, 2023	32,958,288	147
Stock based compensation
Warrants issued for debt discount
Proceeds from issuance of Preferred stock
Dividends payable on Preferred Stock			(23,209)		(23,209)
Net loss				(1,205,343)	(1,205,343)
Balance at Mar. 31, 2024	$ 32,958	$ 1	35,346,786	(65,138,349)	(29,758,604)
Balance, shares at Mar. 31, 2024	32,958,288	141
Balance at Dec. 31, 2023	$ 32,958	$ 1	35,369,995	(63,933,006)	(28,530,052)
Balance, shares at Dec. 31, 2023	32,958,288	147
Net loss					(3,067,704)
Balance at Jun. 30, 2024	$ 32,958	$ 1	35,323,580	(67,000,710)	(31,644,171)
Balance, shares at Jun. 30, 2024	32,958,288	147
Balance at Mar. 31, 2024	$ 32,958	$ 1	35,346,786	(65,138,349)	(29,758,604)
Balance, shares at Mar. 31, 2024	32,958,288	141
Stock based compensation
Warrants issued for debt discount
Proceeds from issuance of Preferred stock			(23,206)		(23,206)
Net loss				(1,862,361)	(1,862,361)
Balance at Jun. 30, 2024	$ 32,958	$ 1	$ 35,323,580	$ (67,000,710)	$ (31,644,171)
Balance, shares at Jun. 30, 2024	32,958,288	147

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (3,067,704)	$ (4,676,009)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation	17,364	27,442
Loss on disposition of assets		99,876
Amortization of debt discount	162,626	1,346,861
Amortization of debt discount		(89,991)
Preferred dividends - accrued	46,416	44,316
Provision for bad debts	1,506	35,103
Changes in operating assets and liabilities:
Accounts receivable	8,964	1,159,875
Other current assets	(262,306)	28,436
(Increase) decrease in leased assets	158,112	1,847,383
Accounts payable and accrued liabilities	2,448,401	(377,006)
(Increase) decrease in lease liabilities	(146,970)	(1,619,770)
Net cash provided by (used in) operating activities	(633,591)	(2,173,484)
Cash flows from investing activities:
Proceeds from sale of fixed assets		33,000
Purchase of property and equipment		(3,794)
Net cash (used in) provided by investing activities		29,206
Cash flows from financing activities:
Payments on notes payable		(173,764)
Proceeds from issuance of convertible notes	622,500	2,272,481
Proceeds from sale of preferred stock		45,000
Net cash provided by (used in) financing activities	622,500	2,143,717
Net change in cash	(11,091)	(561)
Cash, beginning of period	12,607	7,219
Cash, end of period	1,516	6,658
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for income taxes
Supplemental disclosure of cash flow information:
Note Payable addition from OID	155,625	258,462
Warrants issued for debt discount		1,672
Common shares issued for convertible notes - inducement	$ 8,406	$ 900

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
BASIS OF PRESENTATION	NOTE 1 — BASIS OF PRESENTATION First Choice Healthcare Solutions, Inc. (“FCHS,” “the Company,” “we,” “our” or “us”) is actively engaged in implementing a defined growth strategy aimed at building a network of localized, integrated healthcare services platforms, comprised of nurse practitioner driven primary care clinics providing services including family primary care, anti-aging, dermatology, weight loss, hormone replacement therapy, functional and genetic testing, nutritional counseling, as well as behavioral health. The unaudited condensed consolidated financial statements of First Choice Healthcare Solutions, Inc., a Delaware The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all the information and disclosures required by U.S. GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of June 30, 2024 and for the three and six months ended June 30, 2024 and 2023. The results of operations for the six months ended June 30, 2024 are not necessarily indicative of the operating results for the full year ending December 31, 2024 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, 2023, and for the year then ended, which were filed with the Securities and Exchange Commission (“SEC”) on Form 10-K on May 13, 2024.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES Use of estimates The preparation of the financial statements in conformity with U. S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates include the recoverability and useful lives of long-lived assets, provision against bad debt, the fair value of the Company’s stock, and stock-based compensation. Actual results may differ from these estimates. Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification No. 606, “Revenue from Contracts with Customers”, when: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. Patient Service Revenue Our revenues relate to (i) net patient fees received from various third-party payers and patients themselves under contracts in which our performance obligations are to provide services to the patients and (ii) and patient fees, co-pays, and deductibles paid by patients themselves. Revenues are recorded during the period our obligations to provide services are satisfied. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and provide for payments based upon predetermined rates for services or discounted fee-for-service rates. Gross revenues are recorded at our standard rates upon completion of the performance obligations to the patients, and an estimate of the discounts applicable to third-party payers is recorded as contra revenue in the same period, based on the contractual arrangements with those third-party payers. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. The payment terms with third party payers typically involve processing time allowances resulting in payment within 30 to 60 days from the date of service. The payment terms with patients provides for services fees, co-pays, and deductibles to be due at the time of service. FIRST CHOICE HEALTHCARE SOLUTIONS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited) Concentrations of credit risk The Company’s financial instruments are exposed to a concentration of customer risk and accounts receivable risk. Occasionally, the Company’s cash and cash equivalents in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. Accounts receivables Accounts receivables are carried at their estimated collectible amounts net of doubtful accounts. The Company analyzes its history and identifies trends for each major payer sources of revenue to estimate the appropriate allowance for doubtful accounts and provision for bad debts. Management regularly reviews data about these major payer sources of revenue in evaluating the sufficiency of the contractual allowances. Patient receivables are accounts receivables from services provided to patients who have third-party coverage. The Company analyzes contractually due amounts and provides a provision for bad debts, if necessary. The Company records a provision for bad debts in the period of service on the basis of past experience or when indications are the patients are unable or unwilling to pay the portion of their bill for which they are responsible. The difference between the standard rates (or the discounted rates if negotiated) and the amounts actually collected after all reasonable collection efforts have been exhausted, is charged off against the allowance for doubtful accounts. Net loss per share Basic net loss per common share is based upon the weighted-average number of common shares outstanding. Diluted net income per common share is based on the weighted-average number of common shares outstanding and potentially dilutive common shares outstanding and computed as follows: SCHEDULE OF BASIC NET LOSS PER COMMON SHARE 2024 2023 Six months ended June 30, 2024 2023 Numerator: Net loss attributable to First Choice Healthcare Solutions, Inc. common shareholders $ (3,114,119 ) $ (4,720,324 ) Denominator: Weighted-average common shares, basic 32,958,288 32,958,288 Weighted-average common shares, diluted 32,958,288 32,958,288 Basic: $ (0.09 ) $ (0.14 ) Diluted: $ (0.09 ) $ (0.14 ) FIRST CHOICE HEALTHCARE SOLUTIONS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (Unaudited) The computation excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Basic net loss per share is computed on the basis of the weighted average number of common shares outstanding during each year. Diluted net loss per share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company uses the “if-converted” method for calculating the earnings per share impact of outstanding convertible debentures, whereby the securities are assumed converted and an earnings per incremental share is computed. Options, warrants and their equivalents are included in EPS calculations through the treasury stock method. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. In addition, there were no vested restricted stock for periods presented. Potentially dilutive securities excluded from the basic and diluted net income per share are as follows: SCHEDULE OF ANTI-DILUTIVE WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING June 30, 2024 December 31, 2023 Convertible debt 2,811,426,942 2,810,648,817 Warrants to purchase common stock 12,894,477 11,774,164 Incentive shares payable issued with convertible notes 4,464,625 1,568,250 Restricted stock awards 1,357,308 1,357,308 Options to purchase common stock — — Total 2,830,143,352 2,825,348,539 Stock-based compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the consolidated statements of operations, as if such amounts were paid in cash. Upon exercise of a common stock equivalent, the Company issues new shares of common stock out of its authorized shares. Long-lived assets The Company follows a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 15 The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. FIRST CHOICE HEALTHCARE SOLUTIONS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (Unaudited) Leases In February 2016, the FASB issued ASC 842, Leases . In accordance with ASC 842, the Company determines if an arrangement is a lease at inception. Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, we estimate incremental borrowing rates corresponding to the reasonably certain lease term. If the estimate of our incremental borrowing rate was changed, our operating lease assets and liabilities could differ materially. Finance leases lease assets and liabilities are recognized at the lease commencement date at the present value of the future lease payments not yet paid using the Company’s incremental borrowing rate, Assets acquired under finance lease are included in property and equipment, while finance lease obligations are included in other current liabilities and other long- term liabilities on the consolidated balance sheets. Income taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company follows a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s consolidated financial statements as of June 30, 2024 and 2023. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date. Treasury Stock The Company uses the cost method when it purchases its own common stock as treasury shares and displays treasury stock as a reduction of shareholders’ equity. Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: ● Level 1 – Quoted prices in active markets for identical assets or liabilities. ● Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. FIRST CHOICE HEALTHCARE SOLUTIONS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (Unaudited) To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. The carrying value of the Company’s cash, accounts receivable, accounts payable, short-term borrowings (including lines of credit and notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity. As of June 30, 2024, and 2023, the Company did not have any items that would be classified as level 1, 2 or 3 disclosures. Reclassifications Certain reclassifications have been made to prior year data to conform to the current year’s presentation. These reclassifications had no impact on reported income or losses. Recent accounting pronouncements The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial position or results of operations.

NOTES PAYABLE AND CAPITAL LEASE

NOTES PAYABLE AND CAPITAL LEASES	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
NOTES PAYABLE AND CAPITAL LEASES	NOTE 3— NOTES PAYABLE AND CAPITAL LEASES Non-Convertible Notes Payable During the years ended December 31, 2022, and December 31, 2021, the Company issued eighteen non-convertible notes payable to individuals for a total face value of $ 2,076,158 408,000 156,000 310,000 817,521 792,637 792,637 PPP Loans In 2020, the Company and its two subsidiaries received Paycheck Protection Plan (“PPP”) loans under the Cares Act totaling $ 1,386,580 103,618 1,283,624 1,283,624 FIRST CHOICE HEALTHCARE SOLUTIONS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (Unaudited) Non-convertible notes payable including accrued interest as of June 30, 2024 and December 31, 2023 are comprised of the following: SCHEDULE OF NON CONVERTIBLE NOTES PAYABLE June 30, 2024 December 31, 2023 Notes Payable $ 3,073,751 $ 2,861,425 Note Payable - Equipment - - PPP Loans Payable 1,338,062 1,331,318 Less current portion (3,073,751 ) (2,861,425 ) Long term portion $ 1,338,062 $ 1,331,318 Fees and discounts are deferred and amortized over the life of the related note payable. For non-convertible notes payable, during the three and six months ended June 30, 2024 and 2023, the Company recognized a total of $ 0 0 0 0 0 0 Convertible Notes Payable 10% OID Senior Secured Convertible Notes The Company entered into Security Purchase Agreements with lenders for the sale of 10% original issue discount senior secured promissory notes (“10% Notes”) and warrants to purchase shares of the Company’s common stock equal to 50% of the face value. The 10% Notes accrue interest at 10% per annum payable quarterly, are convertible into shares of the Company’s common stock at the option of the holder at any time at a fixed ceiling price of $0.75 per share. The 10% Notes have full ratchet and anti-dilution provisions, a principal adjustment provision upon default, providing for a principal increase to 110% at maturity if unpaid, 120% at six months if unpaid and 130% at 12 months if unpaid. The 10% Notes were due March 31, 2022 and to date, all default provisions have been waived. The amounts due under the 10% Secured Convertible Notes are secured by assets of the Company pursuant to a security agreement. At June 30, 2024 and December 31, 2023, the balance of 10% notes was $ 5,808,000 5,808,000 2,174,253 1,652,965 260,644 521,288 185,334 360,382 35% OID Super Priority Senior Secured Convertible Notes During the years ended December 31, 2023 and 2022, the Company entered into Security Purchase Agreements with lenders for the sale of 35% original issue discount senior secured promissory notes (“35% Notes”), warrants to purchase shares of the Company’s common and shares of the Company’s common stock as incentives. The 35% Notes have a 35% original issuance discount being amortized to interest expense through maturity, are non-interest bearing, are due at the earlier of six months from the date of issue or upon the occurrence of a liquidity event and are prepayable by the Company at any time at a premium of 120% of the outstanding balance. Upon an occurrence of default, the holder shall have the right to convert the 35% Note and outstanding interest at the lower of a discount to market or subsequent financings. The amounts due under the 35% Notes are secured by assets of the Company pursuant to a security agreement. At June 30, 2024 and December 31, 2023, the balance of 35% notes was $ 5,600,462 5,600,462 0 0 108,379 94,241 0 0 3,548 1,976 0 0 1,819 913 20% OID Senior Secured Convertible Notes Payable During 2023, the Company entered into Security Purchase Agreements with lenders for the sale of 20% original issue discount senior secured promissory notes (“20% Notes”), warrants to purchase shares of the Company’s common stock with a five-year term, exercisable at any time at the option of the holder at a cash exercise price equal to 93.75% of the per share price of Company’s common stock sold to third-party investors in a qualified financing and incentive shares of the Company’s common stock. The 20% Notes accrue interest at 10% per annum, principal and interest are due at the earlier of six months from the date of issue or upon the occurrence of a liquidity event. FIRST CHOICE HEALTHCARE SOLUTIONS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (Unaudited) The holder shall have the right to convert the 20% Notes and outstanding interest on a qualified financing at a price equal to 85% of the offering price, or a 15% discount to the volume weighted average price of the Company’s common stock for the five days preceding the dates of conversions, subject to a maximum price of $1.00. The amounts due under the 20% Notes are secured by assets of the Company pursuant to a security agreement. During the six months ended June 30, 2024, the Company issued 20% Notes with a face value of $ 778,125 155,625 622,500 1,120,313 2,240,625 1,246,375 468,250 85,000 77,999 41,606 1,727 The original issuance discount, relative fair value of the warrants and incentive shares are being amortized to interest expense through maturity. During the three and six months ended June 30, 2024 and 2023, the Company recognized $ 57,812 162,626 0 0 559 7,846 0 0 Convertible notes payable are comprised of the following: SCHEDULE OF CONVERTIBLE NOTES PAYABLE June 30, 2024 December 31, 2023 10% OID Senior Convertible Notes Payable, past due, interest at 10%, secured by assets, convertible at $0.75 per share $ 5,808,000 $ 5,808,000 10% OID Senior Convertible Notes Payable, past due, interest at 10 0.75 $ 5,808,000 $ 5,808,000 35% OID Super Priority Senior Convertible Notes Payable, due in 2 35 5,600,462 5,600,462 20% OID Senior Convertible Notes Payable, past due, interest at 10 1.00 1,246,375 468,250 Total 12,654,837 11,876,712 Less: unamortized discounts (77,999 ) (85,000 ) Total $ 12,576,838 $ 11,791,712 Less current portion (12,576,838 ) (11,791,712 ) Long-term portion $ - $ -

LEASES

LEASES	6 Months Ended
	Jun. 30, 2024
Leases
LEASES	NOTE 4— LEASES Operating Leases As a result of the adoption of ASC 842 on January 1, 2021, the Company recognized a lease liability which represents the present value of the remaining operating lease payments discounted using our incremental borrowing rate of 5.0 Operating leases consist of an office and a clinic location and have remaining terms of approximately 7 1 FIRST CHOICE HEALTHCARE SOLUTIONS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (Unaudited) Maturities of the above lease liabilities are as follows as of June 30, 2024: SCHEDULE OF MATURITIES OF LEASE LIABILITIES 2024 $ 172,867 2025 596,223 2026 368,340 2027 377,442 Thereafter 1,379,415 Total Lease Payments 2,894,287 Less Interest (299,495 ) Total Lease Liabilities $ 2,594,792 Less: Current Portion (297,501 ) Long-Term Liabilities $ 2,297,291 Sale/Leaseback On March 31, 2016, the Company entered into a lease of Marina Towers under a sale/leaseback transaction, via a 10-year absolute triple-net master lease agreement, to expire in 2026. The Company has two successive options to renew the lease for five-year periods on the same terms and conditions and did not have any residual interest or the option to repurchase the facility at the end of the lease term. During October 2021, the Company, through the eighteenth judicial circuit court in Brevard County, Florda, received an order approving joint stipulation for alternative resolution to the Company’s real estate lease in Melbourne, Florida. The order terminated the Company’s use of floors three and four of the building immediately, while terminating its right to possession and use of floors one, two and five at December 31, 2021. The order also terminated the existing lease payment schedule, replacing it with the following: ● Payment of $ 50,000 ● The following rent installment payments: SCHEDULE OF RENT INSTALLMENT PAYMENTS I. $ 200,000 II. $ 250,000 III. $ 306,166 IV. $ 275,000 V. $ 31,166 VI. $ 300,000 VII. $ 31,166 Upon receipt of the order, the Company recorded a liability and lease settlement expense for the amount of the order, or $ 1,443,498 200,000 1,200,000

CAPITAL STOCK

CAPITAL STOCK	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
CAPITAL STOCK	NOTE 5 — CAPITAL STOCK Series A Preferred Convertible Stock The Company is authorized to issue 40,000 0.01 Each share of the Series A preferred stock is convertible into 10,000 10 FIRST CHOICE HEALTHCARE SOLUTIONS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (Unaudited) During the six months ended June 30, 2024 and June 30, 2023, the Company did not issue any shares of Series A preferred stock. As of June 30, 2024 and 2023, the total Series A preferred shares outstanding were 147 147 Common stock During the six months ended June 30, 2024 and June 30, 2023, the Company did not issue any shares of its common stock. In connection with the issuance of the 20% OID Convertible Notes in 2023, the Company was to issue 468,250 2,240,625

STOCK OPTIONS, WARRANTS AND RES

STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS	6 Months Ended
	Jun. 30, 2024
Stock Options Warrants And Restricted Stock Units
STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS	NOTE 6 — STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS Options The Company does not have an Incentive Stock Plan in place. Restricted Stock Units (“RSU”) Transactions involving restricted stock units issued are summarized as follows: SCHEDULE OF RESTRICTED STOCK UNITS ISSUES Restricted share units as of December 31, 2023 1,357,308 Granted — Forfeited — Unvested restricted shares as of June 30, 2024 1,357,308 During the six months ended June 30, 2024, the Company granted 0 As of June 30, 2024, stock-based compensation related to restricted stock awards of $ 0 Warrants The Company issued warrants in 2024 and 2023 to employees, consultants, and in connection with debt issuances. Warrants to purchase shares of the Company’s common stock warrants have a five-year term, are fully vested upon issuance, exercisable upon the completion of a qualified financing typically at a cash exercise price equal to 93.75 1,120,313 294,231 0 1,672 Transactions involving stock warrants issued are summarized as follows: SCHEDULE OF STOCK WARRANT ISSUED Number of Shares Outstanding at December 31, 2023: 11,774,164 Issued 1,120,313 Exercised — Forfeited — Expired — Outstanding at June 30, 2024: 12,984,477 FIRST CHOICE HEALTHCARE SOLUTIONS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (Unaudited)

GOING CONCERN

GOING CONCERN	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 7 – GOING CONCERN The accompanying consolidated financial statements have been prepared on a going concern basis of accounting which contemplates continuity of operations, realization of assets, liabilities, and commitments in the normal course of business. The accompanying consolidated financial statements do not reflect any adjustments that might result if the Company is unable to continue as a going concern. The Company has a working capital deficit of $ 30,699,329 During the three and six months ended June 30, 2024, the Company experienced net operating losses of approximately $ 1,862,361 3,067,704 554,645 633,591 67,000,708 However, in order to execute the Company’s business development plan, which there can be no assurance we will achieve, the Company may need to raise additional funds through public or private equity offerings, debt financings, corporate collaborations or other means and potentially reduce operating expenditures. If the Company is unable to secure additional capital, it may have to curtail its business development initiatives and take additional measures to reduce costs in order to conserve its cash, thus raising substantial doubt about its ability to continue as a going concern more than one year from the date of issuance of the June 30, 2024 financial statements included in this filing.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 – SUBSEQUENT EVENTS Proposed Series C Preferred Convertible Stock. In July 2024, contingent to a qualified financing occurring no later than six months from the exchange agreement date, the Company proposed the exchange of (i) all outstanding 10% Senior Secured Convertible Notes including accrued interest, (ii) all outstanding 35% Senior Secured Convertible Notes including accrued interest, (iii) all outstanding Promissory Notes including accrued interest, (iv) all outstanding Series A Preferred Convertible Stock including accrued dividends payable, and (v) certain open trade payables, for shares of a newly proposed Series C preferred stock with an exchange value of $1,000 per share. The proposed exchange value of (i), (ii), (iii), and (iv) above included a 35% premium to the book value of those instruments. The proposed exchange also included the exchange of all warrants to purchase common stock and incentive shares payable, each previously issued in conjunction with (i), (ii), (iii), and (iv) above for new warrants at a quantity calculated at 50% of the original face value of each of the notes and a holder’s initial investment in the Series A Preferred Convertible Stock. The proposed exchange agreements all stated that the proposed exchange would be null and void if the Company did not close a qualified financing within six months from the exchange agreement date.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Use of estimates	Use of estimates The preparation of the financial statements in conformity with U. S. GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Significant estimates include the recoverability and useful lives of long-lived assets, provision against bad debt, the fair value of the Company’s stock, and stock-based compensation. Actual results may differ from these estimates.
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification No. 606, “Revenue from Contracts with Customers”, when: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management’s judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
Patient Service Revenue	Patient Service Revenue Our revenues relate to (i) net patient fees received from various third-party payers and patients themselves under contracts in which our performance obligations are to provide services to the patients and (ii) and patient fees, co-pays, and deductibles paid by patients themselves. Revenues are recorded during the period our obligations to provide services are satisfied. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the transaction prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges and provide for payments based upon predetermined rates for services or discounted fee-for-service rates. Gross revenues are recorded at our standard rates upon completion of the performance obligations to the patients, and an estimate of the discounts applicable to third-party payers is recorded as contra revenue in the same period, based on the contractual arrangements with those third-party payers. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. The payment terms with third party payers typically involve processing time allowances resulting in payment within 30 to 60 days from the date of service. The payment terms with patients provides for services fees, co-pays, and deductibles to be due at the time of service. FIRST CHOICE HEALTHCARE SOLUTIONS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (unaudited)
Concentrations of credit risk	Concentrations of credit risk The Company’s financial instruments are exposed to a concentration of customer risk and accounts receivable risk. Occasionally, the Company’s cash and cash equivalents in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.
Accounts receivables	Accounts receivables Accounts receivables are carried at their estimated collectible amounts net of doubtful accounts. The Company analyzes its history and identifies trends for each major payer sources of revenue to estimate the appropriate allowance for doubtful accounts and provision for bad debts. Management regularly reviews data about these major payer sources of revenue in evaluating the sufficiency of the contractual allowances. Patient receivables are accounts receivables from services provided to patients who have third-party coverage. The Company analyzes contractually due amounts and provides a provision for bad debts, if necessary. The Company records a provision for bad debts in the period of service on the basis of past experience or when indications are the patients are unable or unwilling to pay the portion of their bill for which they are responsible. The difference between the standard rates (or the discounted rates if negotiated) and the amounts actually collected after all reasonable collection efforts have been exhausted, is charged off against the allowance for doubtful accounts.
Net loss per share	Net loss per share Basic net loss per common share is based upon the weighted-average number of common shares outstanding. Diluted net income per common share is based on the weighted-average number of common shares outstanding and potentially dilutive common shares outstanding and computed as follows: SCHEDULE OF BASIC NET LOSS PER COMMON SHARE 2024 2023 Six months ended June 30, 2024 2023 Numerator: Net loss attributable to First Choice Healthcare Solutions, Inc. common shareholders $ (3,114,119 ) $ (4,720,324 ) Denominator: Weighted-average common shares, basic 32,958,288 32,958,288 Weighted-average common shares, diluted 32,958,288 32,958,288 Basic: $ (0.09 ) $ (0.14 ) Diluted: $ (0.09 ) $ (0.14 ) FIRST CHOICE HEALTHCARE SOLUTIONS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (Unaudited) The computation excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Basic net loss per share is computed on the basis of the weighted average number of common shares outstanding during each year. Diluted net loss per share is computed similar to basic net loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company uses the “if-converted” method for calculating the earnings per share impact of outstanding convertible debentures, whereby the securities are assumed converted and an earnings per incremental share is computed. Options, warrants and their equivalents are included in EPS calculations through the treasury stock method. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. In addition, there were no vested restricted stock for periods presented. Potentially dilutive securities excluded from the basic and diluted net income per share are as follows: SCHEDULE OF ANTI-DILUTIVE WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING June 30, 2024 December 31, 2023 Convertible debt 2,811,426,942 2,810,648,817 Warrants to purchase common stock 12,894,477 11,774,164 Incentive shares payable issued with convertible notes 4,464,625 1,568,250 Restricted stock awards 1,357,308 1,357,308 Options to purchase common stock — — Total 2,830,143,352 2,825,348,539
Stock-based compensation	Stock-based compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the consolidated statements of operations, as if such amounts were paid in cash. Upon exercise of a common stock equivalent, the Company issues new shares of common stock out of its authorized shares.
Long-lived assets	Long-lived assets The Company follows a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives of 5 15 The Company evaluates the recoverability of long-lived assets based upon forecasted undiscounted cash flows. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. Assets to be disposed of are reported at the lower of the carrying amount or the fair value less costs to sell. FIRST CHOICE HEALTHCARE SOLUTIONS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (Unaudited)
Leases	Leases In February 2016, the FASB issued ASC 842, Leases . In accordance with ASC 842, the Company determines if an arrangement is a lease at inception. Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, we estimate incremental borrowing rates corresponding to the reasonably certain lease term. If the estimate of our incremental borrowing rate was changed, our operating lease assets and liabilities could differ materially. Finance leases lease assets and liabilities are recognized at the lease commencement date at the present value of the future lease payments not yet paid using the Company’s incremental borrowing rate, Assets acquired under finance lease are included in property and equipment, while finance lease obligations are included in other current liabilities and other long- term liabilities on the consolidated balance sheets.
Income taxes	Income taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of items that have been included or excluded in the financial statements or tax returns. Deferred tax assets and liabilities are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (“temporary differences”) at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company follows a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management has evaluated and concluded that there were no material uncertain tax positions requiring recognition in the Company’s consolidated financial statements as of June 30, 2024 and 2023. The Company does not expect any significant changes in its unrecognized tax benefits within twelve months of the reporting date.
Treasury Stock	Treasury Stock The Company uses the cost method when it purchases its own common stock as treasury shares and displays treasury stock as a reduction of shareholders’ equity.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: ● Level 1 – Quoted prices in active markets for identical assets or liabilities. ● Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. FIRST CHOICE HEALTHCARE SOLUTIONS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2024 (Unaudited) To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. The carrying value of the Company’s cash, accounts receivable, accounts payable, short-term borrowings (including lines of credit and notes payable), and other current assets and liabilities approximate fair value because of their short-term maturity. As of June 30, 2024, and 2023, the Company did not have any items that would be classified as level 1, 2 or 3 disclosures.
Reclassifications	Reclassifications Certain reclassifications have been made to prior year data to conform to the current year’s presentation. These reclassifications had no impact on reported income or losses.
Recent accounting pronouncements	Recent accounting pronouncements The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements. The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial position or results of operations.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
SCHEDULE OF BASIC NET LOSS PER COMMON SHARE	Basic net loss per common share is based upon the weighted-average number of common shares outstanding. Diluted net income per common share is based on the weighted-average number of common shares outstanding and potentially dilutive common shares outstanding and computed as follows: SCHEDULE OF BASIC NET LOSS PER COMMON SHARE 2024 2023 Six months ended June 30, 2024 2023 Numerator: Net loss attributable to First Choice Healthcare Solutions, Inc. common shareholders $ (3,114,119 ) $ (4,720,324 ) Denominator: Weighted-average common shares, basic 32,958,288 32,958,288 Weighted-average common shares, diluted 32,958,288 32,958,288 Basic: $ (0.09 ) $ (0.14 ) Diluted: $ (0.09 ) $ (0.14 )
SCHEDULE OF ANTI-DILUTIVE WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING	SCHEDULE OF ANTI-DILUTIVE WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING June 30, 2024 December 31, 2023 Convertible debt 2,811,426,942 2,810,648,817 Warrants to purchase common stock 12,894,477 11,774,164 Incentive shares payable issued with convertible notes 4,464,625 1,568,250 Restricted stock awards 1,357,308 1,357,308 Options to purchase common stock — — Total 2,830,143,352 2,825,348,539

NOTES PAYABLE AND CAPITAL LEA_2

NOTES PAYABLE AND CAPITAL LEASES (Tables)	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
SCHEDULE OF NON CONVERTIBLE NOTES PAYABLE	Non-convertible notes payable including accrued interest as of June 30, 2024 and December 31, 2023 are comprised of the following: SCHEDULE OF NON CONVERTIBLE NOTES PAYABLE June 30, 2024 December 31, 2023 Notes Payable $ 3,073,751 $ 2,861,425 Note Payable - Equipment - - PPP Loans Payable 1,338,062 1,331,318 Less current portion (3,073,751 ) (2,861,425 ) Long term portion $ 1,338,062 $ 1,331,318
SCHEDULE OF CONVERTIBLE NOTES PAYABLE	Convertible notes payable are comprised of the following: SCHEDULE OF CONVERTIBLE NOTES PAYABLE June 30, 2024 December 31, 2023 10% OID Senior Convertible Notes Payable, past due, interest at 10%, secured by assets, convertible at $0.75 per share $ 5,808,000 $ 5,808,000 10% OID Senior Convertible Notes Payable, past due, interest at 10 0.75 $ 5,808,000 $ 5,808,000 35% OID Super Priority Senior Convertible Notes Payable, due in 2 35 5,600,462 5,600,462 20% OID Senior Convertible Notes Payable, past due, interest at 10 1.00 1,246,375 468,250 Total 12,654,837 11,876,712 Less: unamortized discounts (77,999 ) (85,000 ) Total $ 12,576,838 $ 11,791,712 Less current portion (12,576,838 ) (11,791,712 ) Long-term portion $ - $ -

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2024
Leases
SCHEDULE OF MATURITIES OF LEASE LIABILITIES	Maturities of the above lease liabilities are as follows as of June 30, 2024: SCHEDULE OF MATURITIES OF LEASE LIABILITIES 2024 $ 172,867 2025 596,223 2026 368,340 2027 377,442 Thereafter 1,379,415 Total Lease Payments 2,894,287 Less Interest (299,495 ) Total Lease Liabilities $ 2,594,792 Less: Current Portion (297,501 ) Long-Term Liabilities $ 2,297,291
SCHEDULE OF RENT INSTALLMENT PAYMENTS	SCHEDULE OF RENT INSTALLMENT PAYMENTS I. $ 200,000 II. $ 250,000 III. $ 306,166 IV. $ 275,000 V. $ 31,166 VI. $ 300,000 VII. $ 31,166 Upon receipt of the order, the Company recorded a liability and lease settlement expense for the amount of the order, or $ 1,443,498 200,000 1,200,000

STOCK OPTIONS, WARRANTS AND R_2

STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Tables)	6 Months Ended
	Jun. 30, 2024
Stock Options Warrants And Restricted Stock Units
SCHEDULE OF RESTRICTED STOCK UNITS ISSUES	Transactions involving restricted stock units issued are summarized as follows: SCHEDULE OF RESTRICTED STOCK UNITS ISSUES Restricted share units as of December 31, 2023 1,357,308 Granted — Forfeited — Unvested restricted shares as of June 30, 2024 1,357,308
SCHEDULE OF STOCK WARRANT ISSUED	Transactions involving stock warrants issued are summarized as follows: SCHEDULE OF STOCK WARRANT ISSUED Number of Shares Outstanding at December 31, 2023: 11,774,164 Issued 1,120,313 Exercised — Forfeited — Expired — Outstanding at June 30, 2024: 12,984,477

SCHEDULE OF BASIC NET LOSS PER

SCHEDULE OF BASIC NET LOSS PER COMMON SHARE (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Accounting Policies [Abstract]
Net loss attributable to First Choice Healthcare Solutions, Inc. common shareholders	$ (1,885,567)	$ (2,677,679)	$ (3,114,119)	$ (4,720,324)
Weighted-average common shares, basic	32,958,288	32,958,288	32,958,288	32,958,288
Weighted-average common shares, diluted	32,958,288	32,958,288	32,958,288	32,958,288
Basic:	$ (0.06)	$ (0.08)	$ (0.09)	$ (0.14)
Diluted:	$ (0.06)	$ (0.08)	$ (0.09)	$ (0.14)

SCHEDULE OF ANTI-DILUTIVE WEIGH

SCHEDULE OF ANTI-DILUTIVE WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING (Details) - shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,830,143,352	2,825,348,539
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,811,426,942	2,810,648,817
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	12,894,477	11,774,164
Incentive Shares Payable Issued With Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,464,625	1,568,250
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,357,308	1,357,308
Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total

BASIS OF PRESENTATION (Details

BASIS OF PRESENTATION (Details Narrative)	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Entity incorporation, state or country code	DE

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	Jun. 30, 2024
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	15 years

SCHEDULE OF NON CONVERTIBLE NOT

SCHEDULE OF NON CONVERTIBLE NOTES PAYABLE (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Notes Payable	$ 3,073,751	$ 2,861,425
Note Payable - Equipment
PPP Loans Payable	1,338,062	1,331,318
Less current portion	(3,073,751)	(2,861,425)
Long term portion	$ 1,338,062	$ 1,331,318

SCHEDULE OF CONVERTIBLE NOTES P

SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Total
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Total	12,654,837	11,876,712
Less: unamortized discounts	(77,999)	(85,000)
Total	12,576,838	11,791,712
Less current portion	(12,576,838)	(11,791,712)
Long-term portion
Convertible Notes Payable [Member] | 10% OID Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Total	5,808,000	5,808,000
Convertible Notes Payable [Member] | 35% OID Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Total	5,600,462	5,600,462
Convertible Notes Payable [Member] | 20% OID Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Total	$ 1,246,375	$ 468,250

SCHEDULE OF CONVERTIBLE NOTES_2

SCHEDULE OF CONVERTIBLE NOTES PAYABLE (Details) (Parenthetical) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
10% OID Senior Secured Convertible Notes [Member]
Short-Term Debt [Line Items]
Interest rate	10%	10%
Interest rate	$ 0.75	$ 0.75
35 % OID Super Priority Senior Secured Convertible Notes [Member]
Short-Term Debt [Line Items]
Interest rate	35%	35%
Debt instrument term	2 years	2 years
20% OID Senior Secured Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Interest rate	10%	10%
Interest rate	$ 1	$ 1

NOTES PAYABLE AND CAPITAL LEA_3

NOTES PAYABLE AND CAPITAL LEASES (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended		12 Months Ended
	Feb. 19, 2021	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Balance of 20% notes		$ 3,073,751		$ 3,073,751		$ 2,861,425
PPP loans payable		1,283,624		1,283,624		1,283,624
Interest expense from amortization				162,626	$ 1,346,861
Paycheck Protection Plan Loan [Member]
Debt Instrument [Line Items]
Debt discount		0		0		0
Proceeds from loans	$ 103,618								$ 1,386,580
Amortization of original issuance debt discounts		0	$ 0	0	0
Eighteen Non-Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt instrument face amount							$ 2,076,158	$ 2,076,158
Debt discount							408,000
Non Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Repayments of debt						156,000	$ 310,000	$ 817,521
Balance of 20% notes		792,637	792,637	$ 792,637	792,637
10% OID Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Debt instrument description				The Company entered into Security Purchase Agreements with lenders for the sale of 10% original issue discount senior secured promissory notes (“10% Notes”) and warrants to purchase shares of the Company’s common stock equal to 50% of the face value. The 10% Notes accrue interest at 10% per annum payable quarterly, are convertible into shares of the Company’s common stock at the option of the holder at any time at a fixed ceiling price of $0.75 per share. The 10% Notes have full ratchet and anti-dilution provisions, a principal adjustment provision upon default, providing for a principal increase to 110% at maturity if unpaid, 120% at six months if unpaid and 130% at 12 months if unpaid. The 10% Notes were due March 31, 2022 and to date, all default provisions have been waived. The amounts due under the 10% Secured Convertible Notes are secured by assets of the Company pursuant to a security agreement.
Balance of 35% notes		5,808,000		$ 5,808,000		5,808,000
Accrued interest		2,174,253		2,174,253		1,652,965
Interest expense from amortization.		260,644	185,334	$ 521,288	360,382
35 % OID Super Priority Senior Secured Convertible Notes [Member]
Debt Instrument [Line Items]
Debt instrument description				During the years ended December 31, 2023 and 2022, the Company entered into Security Purchase Agreements with lenders for the sale of 35% original issue discount senior secured promissory notes (“35% Notes”), warrants to purchase shares of the Company’s common and shares of the Company’s common stock as incentives. The 35% Notes have a 35% original issuance discount being amortized to interest expense through maturity, are non-interest bearing, are due at the earlier of six months from the date of issue or upon the occurrence of a liquidity event and are prepayable by the Company at any time at a premium of 120% of the outstanding balance. Upon an occurrence of default, the holder shall have the right to convert the 35% Note and outstanding interest at the lower of a discount to market or subsequent financings. The amounts due under the 35% Notes are secured by assets of the Company pursuant to a security agreement.
Balance of 35% notes		5,600,462		$ 5,600,462		5,600,462
Interest expense from amortization.		0	0	108,379	94,241
Amortization of debt discounts from warrants		0	0	3,548	1,976
Amortization of incentive shares		0	0	1,819	913
20% OID Senior Secured Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Debt instrument face amount		778,125		778,125
Debt discount		85,000		85,000		77,999
Balance of 20% notes		1,246,375		$ 1,246,375		468,250
Debt instrument description				During 2023, the Company entered into Security Purchase Agreements with lenders for the sale of 20% original issue discount senior secured promissory notes (“20% Notes”), warrants to purchase shares of the Company’s common stock with a five-year term, exercisable at any time at the option of the holder at a cash exercise price equal to 93.75% of the per share price of Company’s common stock sold to third-party investors in a qualified financing and incentive shares of the Company’s common stock. The 20% Notes accrue interest at 10% per annum, principal and interest are due at the earlier of six months from the date of issue or upon the occurrence of a liquidity event.
Warrants exercisable description.				The holder shall have the right to convert the 20% Notes and outstanding interest on a qualified financing at a price equal to 85% of the offering price, or a 15% discount to the volume weighted average price of the Company’s common stock for the five days preceding the dates of conversions, subject to a maximum price of $1.00. The amounts due under the 20% Notes are secured by assets of the Company pursuant to a security agreement.
Debt discount, net		155,625		$ 155,625
Cash		622,500		622,500
Interest payable		41,606		41,606		$ 1,727
Interest expense from amortization		57,812	162,626	0	0
Amortization of incentive shares		$ 559	$ 7,846	$ 0	$ 0
20% OID Senior Secured Convertible Notes Payable [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Purchase of warrants						1,120,313
Common stock, issued				2,240,625

SCHEDULE OF MATURITIES OF LEASE

SCHEDULE OF MATURITIES OF LEASE LIABILITIES (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Leases
2024	$ 172,867
2025	596,223
2026	368,340
2027	377,442
Thereafter	1,379,415
Total Lease Payments	2,894,287
Less Interest	(299,495)
Total Lease Liabilities	2,594,792
Less: Current Portion	(297,501)	$ (299,244)
Long-Term Liabilities	$ 2,297,291	$ 2,442,519

SCHEDULE OF RENT INSTALLMENT PA

SCHEDULE OF RENT INSTALLMENT PAYMENTS (Details) - USD ($)	Feb. 15, 2022	Feb. 08, 2022	Jan. 15, 2022	Jan. 07, 2022	Dec. 15, 2021	Nov. 15, 2021	Oct. 19, 2021
Leases
Rent installment payment.	$ 31,166	$ 300,000	$ 31,166	$ 275,000	$ 306,166	$ 250,000	$ 200,000

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)			6 Months Ended
	Oct. 12, 2021	Mar. 31, 2016	Jun. 30, 2024	Jan. 01, 2021
Property, Plant and Equipment [Line Items]
Operating lease payments				5%
Lease transaction		the Company entered into a lease of Marina Towers under a sale/leaseback transaction, via a 10-year absolute triple-net master lease agreement, to expire in 2026. The Company has two successive options to renew the lease for five-year periods on the same terms and conditions and did not have any residual interest or the option to repurchase the facility at the end of the lease term.
Operating lease payments	$ 50,000
Lease settlement expense			$ 1,443,498
Contractual obligation			200,000
Accounts payable			$ 1,200,000
Office [Member]
Property, Plant and Equipment [Line Items]
Operating lease term				7 years
Clinic Location [Member]
Property, Plant and Equipment [Line Items]
Operating lease term				1 year

CAPITAL STOCK (Details Narrativ

CAPITAL STOCK (Details Narrative) - $ / shares	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Class of Stock [Line Items]
Preferred stock, shares authorized	40,000	40,000
Preferred stock, par or stated value per share	$ 0.01	$ 0.01
Preferred shares, outstanding	147	147
Common Stock [Member] | 35% OID Super Priority Convertible Notes 2022 [Member]
Class of Stock [Line Items]
Issuance of common stock	468,250
Common Stock [Member] | 35% OID Super Priority Convertible Notes 2023 [Member]
Class of Stock [Line Items]
Issuance of common stock	2,240,625
Series A Preferred Convertible Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized	40,000
Preferred stock, par or stated value per share	$ 0.01
Series A Preferred Convertible Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Conversion of preferred stock	10,000
Series A 10% Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Dividend rate	10%
Series A Preferred Stock [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Preferred shares, outstanding	147		147

SCHEDULE OF RESTRICTED STOCK UN

SCHEDULE OF RESTRICTED STOCK UNITS ISSUES (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Jun. 30, 2024 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted shares units issued, beginning balance	1,357,308
Restricted shares units, granted
Restricted shares units, forfeited
Restricted shares units issued, ending balance	1,357,308

SCHEDULE OF STOCK WARRANT ISSUE

SCHEDULE OF STOCK WARRANT ISSUED (Details) - Warrant [Member]	6 Months Ended
	Jun. 30, 2024 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding, number of shares, beginning balance	11,774,164
Outstanding, number of shares, issued	1,120,313
Outstanding, number of shares, exercised
Outstanding, number of shares, forfeited
Outstanding, number of shares, expired
Outstanding, number of shares, ending balance	12,984,477

STOCK OPTIONS, WARRANTS AND R_3

STOCK OPTIONS, WARRANTS AND RESTRICTED STOCK UNITS (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 93.75
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants issued	1,120,313	294,231
Estimated fair value of warrants issued	$ 0	$ 1,672
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock units
Restricted stock, unamortized	$ 0

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	3 Months Ended			6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital deficit	$ 30,699,329			$ 30,699,329
Operating losses	1,862,361	$ 1,205,343	$ 2,654,958	3,067,704	$ 4,676,009
Cash outflows from operations	554,645			633,591	$ 2,173,484
Accumulated deficit	$ 67,000,708			$ 67,000,708		$ 63,933,006

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)	1 Months Ended
	Jul. 31, 2024
Subsequent Event [Member]
Subsequent Event [Line Items]
Debt conversion description	Proposed Series C Preferred Convertible Stock. In July 2024, contingent to a qualified financing occurring no later than six months from the exchange agreement date, the Company proposed the exchange of (i) all outstanding 10% Senior Secured Convertible Notes including accrued interest, (ii) all outstanding 35% Senior Secured Convertible Notes including accrued interest, (iii) all outstanding Promissory Notes including accrued interest, (iv) all outstanding Series A Preferred Convertible Stock including accrued dividends payable, and (v) certain open trade payables, for shares of a newly proposed Series C preferred stock with an exchange value of $1,000 per share. The proposed exchange value of (i), (ii), (iii), and (iv) above included a 35% premium to the book value of those instruments. The proposed exchange also included the exchange of all warrants to purchase common stock and incentive shares payable, each previously issued in conjunction with (i), (ii), (iii), and (iv) above for new warrants at a quantity calculated at 50% of the original face value of each of the notes and a holder’s initial investment in the Series A Preferred Convertible Stock. The proposed exchange agreements all stated that the proposed exchange would be null and void if the Company did not close a qualified financing within six months from the exchange agreement date.